Weaver Consulting Group Has $468,000 Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

Weaver Consulting Group trimmed its position in Amgen Inc. (NASDAQ:AMGN) by 5.7% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,646 shares of the medical research company’s stock after selling 100 shares during the quarter. Weaver Consulting Group’s holdings in Amgen were worth $468,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the company. Vanguard Group Inc. raised its holdings in Amgen by 0.3% in the 3rd quarter. Vanguard Group Inc. now owns 49,035,981 shares of the medical research company’s stock valued at $13,178,910,000 after acquiring an additional 165,636 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in Amgen by 3.9% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,564,710 shares of the medical research company’s stock valued at $1,890,769,000 after purchasing an additional 243,720 shares during the period. Royal Bank of Canada grew its holdings in Amgen by 14.8% in the 4th quarter. Royal Bank of Canada now owns 5,831,624 shares of the medical research company’s stock valued at $1,679,625,000 after buying an additional 751,947 shares in the last quarter. Norges Bank bought a new position in Amgen during the 4th quarter worth $1,556,912,000. Finally, California Public Employees Retirement System lifted its holdings in shares of Amgen by 22.0% during the fourth quarter. California Public Employees Retirement System now owns 2,716,088 shares of the medical research company’s stock worth $782,288,000 after buying an additional 490,539 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, SVP Nancy A. Grygiel sold 2,117 shares of the business’s stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $313.09, for a total transaction of $662,811.53. Following the sale, the senior vice president now directly owns 9,883 shares in the company, valued at approximately $3,094,268.47. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 0.69% of the company’s stock.

Amgen Stock Down 0.4 %

NASDAQ AMGN traded down $1.24 on Friday, hitting $312.45. 3,518,174 shares of the company were exchanged, compared to its average volume of 2,437,626. Amgen Inc. has a 12 month low of $218.44 and a 12 month high of $329.72. The company has a current ratio of 1.42, a quick ratio of 0.98 and a debt-to-equity ratio of 11.96. The company has a market cap of $167.61 billion, a PE ratio of 44.64, a PEG ratio of 2.83 and a beta of 0.60. The stock has a fifty day moving average of $301.56 and a 200-day moving average of $292.10.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Thursday, May 2nd. The medical research company reported $3.96 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.76 by $0.20. Amgen had a net margin of 12.74% and a return on equity of 156.21%. The company had revenue of $7.45 billion for the quarter, compared to analysts’ expectations of $7.45 billion. During the same quarter in the prior year, the firm earned $3.98 EPS. The business’s revenue was up 22.0% on a year-over-year basis. As a group, analysts forecast that Amgen Inc. will post 19.47 earnings per share for the current year.

Wall Street Analyst Weigh In

AMGN has been the topic of a number of recent research reports. Morgan Stanley raised their price target on shares of Amgen from $271.00 to $310.00 and gave the stock an “equal weight” rating in a research report on Friday, May 3rd. Truist Financial reiterated a “buy” rating and issued a $320.00 price target on shares of Amgen in a research note on Friday, April 12th. Royal Bank of Canada increased their price target on Amgen from $328.00 to $332.00 and gave the stock an “outperform” rating in a research report on Friday, June 14th. UBS Group lifted their price objective on Amgen from $284.00 to $307.00 and gave the company a “neutral” rating in a report on Friday, May 3rd. Finally, Raymond James started coverage on Amgen in a report on Thursday, March 28th. They set a “market perform” rating on the stock. Ten equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $307.35.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.